Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?

Relapse is the major cause of allogeneic hematopoietic stem cell transplantation failure in high-risk Philadelphia chromosome-positive (Ph+) leukemia. Post-transplant maintenance therapy is a promising strategy. We found maintenance imatinib and dose-reduced newer generation tyrosine kinase inhibitors to be feasible and generally well tolerated. This approach might reduce the incidence of relapse and improve the outcomes after allogeneic hematopoietic stem cell transplantation for high-risk Ph+ leukemia.

Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Zachariah DeFilipp, Amelia A. Langston, Zhengjia Chen, Chao Zhang, Martha L. Arellano, Fuad El Rassi, Christopher R. Flowers, Vamsi K. Kota, Zaid Al-Kadhimi, Rachel Veldman, Anand P. Jillella, Sagar Lonial, Edmund K. Waller, Hanna J. Khoury Tags: Original Study Source Type: research